Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia

British Journal of Psychiatry

Volumn 169, Issue 5, 1996, Pages 610-617

  Heresco Levy, Uriel ^a,c   Javitt, Daniel C ^b   Ermilov, Marina ^c   Mordel, Clara ^c   Horowitz, Avraham ^c   Kelly, Dalia ^c  

^a HEBREW UNIVERSITY   (Israel)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c HERZOG HOSPITAL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLYCINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; THIORIDAZINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; BRAIN; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CROSS-OVER STUDIES; DEPRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0029658545     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.169.5.610     Document Type: Article

References (23)

1. AMERICAN PSYCHIATRIC ASSOCIATION (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). Washington, DC: APA.
2. CARLSSON, M. & CARLSSON, A. (1990) Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophrenia Bulletin, 16, 425-432.
3. CASCELLA, N. G., MACCIARDI, F., CAVALLINI, C., et al (1994) D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. Journal of Neural Transmission - General Section, 95, 105-111.
4. COSTA, J., KHALED, E., SRAMEK, J., et al (1990) An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. Journal of Clinical Psychopharmacology, 10, 71-72.
5. D'SOUZA, C., CHARNEY, D. & KRYSTAL, J. (1995) Glycine site agonists of the NMDA receptor a review. CNS Drug Reviews, 1, 227-260.
6. GOFF, D. C., TSAI, G., MANOACH, D. S., et al (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. American Journal of Psychiatry, 152, 1213-1215.
7. GUY, W. (ed.) (1976) ECDEU Assessment Manual for Psychopharmacology, pp. 534-537. Washington, DC: US Department of Health, Education and Welfare.
8. JAVITT, D. C. & ZUKIN, S. R. (1991) Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 148, 1301-1308.
9. _, ZYLBERMAN, I., ZUKIN, S. R., et al (1994) Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry, 151, 1234-1236.
10. JOHNSON, J. W. & ASHER, P. (1987) Glycine potentiates the NMDA response in cultured mouse brain neurones. Nature, 323, 529-531.
11. KAY, S. R., OPLER, L. A. & FISZBEIN, A. (1987) Positive and Negative Syndrome Scale (PANSS) Rating Manual. San Rafael CA: Social and Behavioral Sciences Documents.
12. KIM, J. S., KORNHUBER, H. H., SCHMID-BURGK, W., et al (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neuroscience Letters, 20, 379-382.
13. KRYSTAL, J. H., KARPER, L. P., SEIBYL, J. P., et al (1994) Subanaesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans: psychomimetic, perceptual, cognitive and neuroendocrine responses. Archives of General Psychiatry, 51, 199-214.
14. LEIDERMAN, E., ZYLBERMAN, I., ZUKIN, S. R., et al (1996) Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open label trial. Biological Psychiatry, 39, 213-215.
15. LINDENMAYER, J. P., BERNSTEIN-HYMAN, R. & GROCHOWSKI, S. (1994) Five-factor model of schizophrenia. Initial validation. Journal of Nervous and Mental Disease, 182, 631-638.
16. OLDENDORPH, W. H. (1971) Brain uptake of radio labelled amino acids, amines and hexoses after arterial injection. American Journal of Physiology, 221, 1629-1639.
17. POTKIN, S. G., COSTA, J., ROY, S., et al (1992) Glycine in treatment of schizophrenia - theory and preliminary results. In Novel Antipsychotic Drugs (ed. H. Y. Meltzer), pp. 179-188. New York: Raven Press.
18. ROSSE, R. B., THENT, S. K., BANAY-SCHWARTZ, M., et al (1989) Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clinical Neuropharmacology, 2, 416-424.
19. SIMPSON, G. M. & ANGUS, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrics Scandinavica, suppl. 212, 11-19.
20. TOTH, E. & LAJTHA, A. (1986) Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochemical Research, 11, 393-400.
21. TSAI, G., PASSANI, L. A., SLUSHER, B. S., et al (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Archives of General Psychiatry, 52, 829-836.
22. ULAS, J. & COTMAN, C. W. (1993) Excitatory amino acid receptors in schizophrenia. Schizophrenia Bulletin, 19, 105-117.
23. WAZIRI, R. (1988) Glycine therapy of schizophrenia. Biological Psychiatry, 23, 210-211.